Invivyd, Inc. is a microcap biotech company focusing on antibody-based treatments for infectious diseases like COVID-19.

Biotechnology is a high-risk, high-reward landscape where innovation determines success. Yet, occasionally, a small player ...

We recently compiled a list of the Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

Invivyd has teamed up with professional football coach Jim Harbaugh to tackle COVID-19 complacency. The biotech, which has ...

Invivyd, Inc. (NASDAQ:IVVD – Get Free Report) was the recipient of unusually large options trading on Thursday. Traders ...

Teaming up to raise awareness of the continuing toll of COVID-19 in America, an ongoing mass disabling event causing an American death ...

Invivyd data shows strong potency and prolonged antibody levels in trials. Q4 Pemgarda revenue rose 48% to $13.8 million.

PEMGARDA™ (pemivibart) net product revenue of $13.8 million, 48% growth over Q3 2024 net product revenue of $9.3 ...

Get Our Latest Stock Report on IVVD Invivyd Price Performance Shares of IVVD stock opened at $2.04 on Thursday. Invivyd has a 1-year low of $0.35 and a 1-year high of $5.10. The stock’s 50-day ...

WALTHAM, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced ...